LIBRETTO-432: A phase 3 study of adjuvant selpercatinib or placebo in stage IB-IIIA RET fusion-positive (RET plus ) NSCLC.

被引：0
|
作者：
Goldman, Jonathan W.
Sands, Jacob
Hallqvist, Andreas
Kim, Hye Ryun
Li, Guoping
Wu, Lin
Su, Weiji
Bayt, Theresa
Yang, Xue-Ning
Hochmair, Maximilian
机构：
[1] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA USA
[2] Dana Farber Canc Inst, Boston, MA USA
[3] Sahlgrens Univ Hosp, Inst Clin Sci, Dept Oncol, Gothenburg, Sweden
[4] Yonsei Univ, Div Med Oncol, Yonsei Canc Ctr, Coll Med, Seoul, South Korea
[5] Third Peoples Hosp Chengdu, Chengdu Inst Resp Hlth, Branch Natl Clin Res Ctr Resp Dis, Chengdu, Peoples R China
[6] Hunan Canc Hosp, Thorac Internal Med Oncol Dept, Changsha, Hunan, Peoples R China
[7] Eli Lilly & Co, Indianapolis, IN USA
[8] Eil Lilly & Co, Indianapolis, IN USA
[9] Southern Med Univ, Guangdong Lung Canc Inst, Guangdong Prov Peoples Hosp, Guangdong Acad Med Sci, Guangzhou, Peoples R China
[10] Klin Floridsdorf, Karl Landsteiner Inst Lung Res & Pulm Oncol, Dept Resp & Crit Care Med, Vienna, Austria
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS8115
引用
收藏
页数：1
相关论文
共 50 条
  • [1] LIBRETTO-432: A phase 3 study of adjuvant selpercatinib or placebo in stage IB-IIIA RET fusion-positive (RET plus ) NSCLC.
    Bayt, Theresa
    Goldman, Jonathan W.
    Sands, Jacob
    Hallqvist, Andreas
    Kim, Hye Ryun
    Li, Guoping
    Wu, Lin
    Su, Weiji
    Yang, Xue-Ning
    Hochmair, Maximilian
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (23_SUPPL) : TPS216 - TPS216
  • [2] LIBRETTO-432: A Placebo-Controlled Phase 3 Study of Adjuvant Selpercatinib in Stage IB-IIIA RET Fusion-Positive NSCLC
    Goldman, J.
    Besse, B.
    Wu, Y.
    Yang, J. C.
    Paz-Ares, L.
    Drilon, A.
    Johnson, M.
    Xia, M.
    Chao, B. H.
    Tsuboi, M.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S975 - S976
  • [3] LIBRETTO-432, a phase III study of adjuvant selpercatinib or placebo in stage IB-IIIA RET fusion-positive non-small-cell lung cancer
    Tsuboi, Masahiro
    Goldman, Jonathan W.
    Wu, Yi-Long
    Johnson, Melissa L.
    Paz-Ares, Luis
    Yang, James Chih-Hsin
    Besse, Benjamin
    Su, Weiji
    Chao, Bo H.
    Drilon, Alexander
    FUTURE ONCOLOGY, 2022, 18 (28) : 3133 - 3141
  • [4] LIBRETTO-001 cohort 7: A single-arm, phase 2 study of neoadjuvant selpercatinib in patients with resectable stage IB-IIIA RET fusion-positive NSCLC.
    Rajaram, Ravi
    Sholl, Lynette M.
    Dacic, Sanja
    Goldman, Jonathan W.
    Tan, Daniel Shao-Weng
    Gautschi, Oliver
    Loong, Herbert H. F.
    De Braud, Filippo G.
    Massarelli, Erminia
    Levy, Benjamin Philip
    Dy, Grace K.
    Kang, Suhyun
    Szymczak, Sylwia
    Chao, Bo H.
    Drilon, Alexander E.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [5] Intracranial Outcomes of 1L Selpercatinib in Advanced RET fusion-positive (RET plus ) NSCLC: LIBRETTO-431 study
    Perol, Maurice
    Solomon, Ben J.
    Goto, Koichi
    Park, Keunchil
    Nadal, Ernest
    Bria, Emilio
    Martin, Claudio
    Bar, Jair
    Williams, Justin
    Puri, Tarun
    Li, Jian
    Uh, Minji
    Lin, Boris
    Zhou, Caicun
    Pruthi, Aarohan
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2024, 20 : 138 - 138
  • [6] Continuation of selpercatinib beyond progression in RET fusion-positive NSCLC: Data from LIBRETTO-001 study
    Drilon, A. E.
    Chan, J.
    Sands, J.
    Tan, D. S. W.
    Weiss, J.
    Solomon, B.
    Kim, Y. J.
    Johnson, M. L.
    Puri, T.
    Sarno, M. A.
    Kang, S.
    Soldatenkova, V.
    Duann, C-W.
    Szymczak, S.
    Subbiah, V.
    Besse, B.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S999 - S999
  • [7] LIBRETTO-431: Selpercatinib in treatment (Tx)-naive patients with RET fusion-positive (RET plus ) non-small cell lung cancer (NSCLC)
    Loong, H. H. F.
    Goto, K.
    Elamin, Y. Y.
    Solomon, B.
    Santini, F. C.
    Soldatenkova, V.
    Sashegyi, A.
    Lin, A. Bence
    Lin, B. K.
    Wolf, J.
    Oxnard, G. R.
    Zhou, C.
    Drilon, A.
    Park, K.
    ANNALS OF ONCOLOGY, 2020, 31 : S893 - S893
  • [8] Intracranial outcomes of 1L selpercatinib in advanced RET fusion-positive NSCLC: LIBRETTO-431 study.
    Uh, Minji
    Perol, Maurice
    Goto, Koichi
    Solomon, Benjamin J.
    Park, Keunchil
    Nadal, Ernest
    Bria, Emilio
    Martin, Claudio
    Bar, Jair
    Williams, Justin
    Puri, Tarun
    Li, Jian
    Lin, Boris K.
    Zhou, Caicun
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (23_SUPPL) : 199 - 199
  • [9] Intracranial outcomes of 1L selpercatinib in advanced RET fusion-positive NSCLC: LIBRETTO-431 study.
    Perol, Maurice
    Goto, Koichi
    Solomon, Benjamin J.
    Park, Keunchil
    Nadal, Ernest
    Bria, Emilio
    Martin, Claudio
    Bar, Jair
    Williams, Justin
    Puri, Tarun
    Li, Jian
    Uh, Minji
    Lin, Boris K.
    Zhou, Caicun
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [10] Randomized phase 3 study of first-line selpercatinib versus chemotherapy and pembrolizumab in RET fusion-positive NSCLC
    Loong, Herbert
    Goto, Koichi
    Solomon, Benjamin
    Park, Keunchil
    Perol, Maurice
    Arriola, Edurne
    Novello, Silvia
    Cheng, Ying
    Ardizzoni, Andrea
    Mak, Milena
    Santini, Fernando
    Elamin, Yasir
    Drilon, Alexander
    Wolf, Juergen
    Han, Baohui
    Han, Hongmei
    Uh, Minji
    Puri, Tarun
    Soldatenkova, Viktoriya
    Zhou, Caicun
    ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 : 246 - 246
12345